ArticleInfection and immunity2003
Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- A brief review on Group A Streptococcus pathogenesis and vaccine development.Royal Society open science · 2021Review
- Novel Models ofMicroorganisms · 2021Article
- Cross-serotype protection against group A Streptococcal infections induced by immunization with SPy_2191.Nature communications · 2020Article
- Streptococcus pyogenes genes that promote pharyngitis in primates.JCI insight · 2020Article
- Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.Microbiology spectrum · 2019Review
- Contribution of cryptic epitopes in designing a group A streptococcal vaccine.Human vaccines & immunotherapeutics · 2018Article
- Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.Journal of the Pediatric Infectious Diseases Society · 2017Article
- Towards developing a vaccine for rheumatic heart disease.Global cardiology science & practice · 2017Review
- Complement inhibition by Sarcoptes scabiei protects Streptococcus pyogenes - An in vitro study to unravel the molecular mechanisms behind the poorly understood predilection of S. pyogenes to infect mite-induced skin lesions.PLoS neglected tropical diseases · 2017Article
- Article
- Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Clinical microbiology reviews · 2014Review
- The group A streptococcal collagen-like protein-1, Scl1, mediates biofilm formation by targeting the extra domain A-containing variant of cellular fibronectin expressed in wounded tissue.Molecular microbiology · 2013Article
- Defense from the Group A Streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor.The Journal of infectious diseases · 2011Article
- Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.The American journal of the medical sciences · 2010Review
- Streptococcal protective antigens (Spa): a new family of type-specific proteins of group A streptococci.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2010Article
- The structure and function of serum opacity factor: a unique streptococcal virulence determinant that targets high-density lipoproteins.Journal of biomedicine & biotechnology · 2010Review
- Detecting key structural features within highly recombined genes.PLoS computational biology · 2007Article
- Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model.Infection and immunity · 2004Article
- Function of the fibronectin-binding serum opacity factor of Streptococcus pyogenes in adherence to epithelial cells.Infection and immunity · 2004Article
- Opacification Domain of Serum Opacity Factor Inhibits Beta-Hemolysis and Contributes to Virulence ofmSphereArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Serum opacity factor (SOF) is a protein expressed by Streptococcus pyogenes that opacifies mammalian serum. SOF is also a virulence factor of S. pyogenes, but it has not been previously shown to elicit a protective immune response. Herein, we report that SOF evokes bactericidal antibodies against S. pyogenes in humans, rabbits, and mice. Rabbit antiserum against purified recombinant SOF2 opsonized SOF-positive M type 2, 4, and 28 S. pyogenes in human blood but had no effect on SOF-negative M type 5 S. pyogenes. Furthermore, affinity-purified human antibodies against SOF2 also opsonized SOF-positive streptococci. A combination of antisera against M2 and SOF2 proteins was dramatically more effective in killing streptococci than either antiserum alone, indicating that antibodies against SOF2 enhance the opsonic efficiency of M protein antibodies. Mice tolerated an intravenous injection of 100 microg of SOF without overt signs of toxicity, and immunization with SOF protected mice against challenge infections with M type 2 S. pyogenes. These data indicate that SOF evokes opsonic antibodies that may protect against infections by SOF-positive serotypes of group A streptococci and suggest that different serotypes of SOF have common epitopes that may be useful vaccine candidates to protect against group A streptococcal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.